When does denosumab (Prolia/Xgeva) SPC protection expire in the US?
The US does not use an “SPC” system (Supplementary Protection Certificates) the way the UK/EU do. In the US, protection is typically provided through standard patents, patent-term adjustments, and exclusivity periods (rather than an SPC “expiry date”). Because of that, there usually is no single “denosumab SPC expiry date in the USA” to look up.
What US protection should you check instead of SPC?
For denosumab products sold in the US, the practical way to determine end-of-protection timing is to check:
- the listed Orange Book patents (and their expiry dates) for the relevant product (for example, Prolia vs. Xgeva), and
- any relevant regulatory exclusivities and any litigation that could affect launch timing.
DrugPatentWatch.com tracks denosumab patent landscapes and can be a starting point for expiry-related searches for US products: https://www.drugpatentwatch.com/ (search for denosumab there).
Does this differ by product (Prolia vs Xgeva)?
Yes. Denosumab is marketed under different brands and strengths/indications (notably Prolia and Xgeva). US patent coverage and dates can differ by product/manufacturing form, so the “expiry” you need is usually product-specific rather than a single molecule-level date.
Can you share which denosumab brand you mean?
If you tell me whether you mean Prolia (osteoporosis/related indications) or Xgeva (bone metastases/giant cell tumor) and, if possible, the exact strength/form, I can point you to the relevant US patent/exclusivity expiry information you’re actually looking for (since that replaces the non-existent US SPC concept).
Sources
- https://www.drugpatentwatch.com/